Apotex - contamination   www.apotexterror.homestead.com         www.pharmaholocaust.com
I live like a walking death in twilight zone / some where in between death and a life being deprived of all Human Rights and Constitutional / Law 
protection by habitual offenders. I was assessed by three (3) independent psychiatrists to eliminate offender's speculations about my insanity 
prompting "delusions" etc. All psychiatrists stated clearly, that I am sane /I do NOT have/had any mental illness. No family history of any.

Dear Sir/Madam, 

Cyclosporine a very strong immunosuppressant drug.
For many years I worked in National Serum and Vaccination Plant in 
managerial capacity with hands on production duties of all human and animal 
immunoglobulin, serums and many vaccines, so I become very alarmed / shocked 
while Apotex announced, that Cyclosporine's
(avery strong immunosuppressant drug widely used in post-allogeneic organ 
transplant to reduce the activity of the patient's immune system, and 
therefore the risk of organ rejection. It has been studied in transplants of 
skin, heart, kidney, liver, lung, pancreas, bone marrow, and small 
intestine. Ciclosporin is a cyclic nonribosomal peptide of 11 amino acids 
and contains a single D-amino acid. Apart from in transplant medicine, 
ciclosporin is also used in psoriasis, severe atopic dermatitis, pyoderma 
gangrenosum, chronic autoimmune urticaria, and, infrequently, in rheumatoid 
arthritis and related diseases.) classification was changed and apparently 
Authorities allowed production of it with out any restrictions/ protection 
in common Manufacturing area / next to production of other products.
Treatment / exposure to Cyclosporine may be associated with a number of 
potentially serious adverse drug reactions (ADRs).
ADRs can include gingival hyperplasia, convulsions, peptic ulcers, 
pancreatitis, fever, vomiting, diarrhea, confusion, hypercholesterolemia, 
dyspnea, numbness and tingling particularly of the lips, pruritus, high 
blood pressure, potassium retention, and possibly hyperkalemia, kidney and 
liver dysfunction (nephrotoxicity& hepatotoxicity), burning sensation at 
finger tips and an increased vulnerability to opportunistic fungal and viral 
I request from Apotex a Carbon Copy of Original industrial manufacturing 
classification for Cyclosporine, which demanded processing of this substance 
in isolated area (with Air Locks in entrances to the Process Rooms, on 
dedicated equipment, with special Air Handling Systems, with special 
protective equipment for Personnel etc.)
During production of Validation Batches in not compliant manner and due to 
massive discharges of this material on the floors it was discovered, that 
product does heavily end up all over the plant including Offices (all over 
the desks of Offices employees) and Personnel had to be evacuated from the 
Apotex in stead of getting its infrastructure modernized and up to 
regulatory compliance announced that apparently did manage to change product's 
classification which apparently removed ALL restrictions / Regulations and 
allowed Apotex to process it with out any considerations for contamination 
of the Personnel and cross contamination of the products. I request Carbon 
Copy of Regulatory Agency's Report (Health Canada? etc.) changing 
classification of the Cyclosporine which permitted Apotex to proceed with 
production of this substance in not controlled / regulated manner.
Cyclosporine Side Effects
Autonomic Nervous System:
Dry mouth, increased sweating
Body as a Whole:
Allergy, asthenia, hot flushes, malaise, overdose, procedure NOS*, tumor 
NOS*, weight decrease, weight increase
Abnormal heart sounds, cardiac failure, myocardial infarction, peripheral 
Central and Peripheral Nervous System :
Hypoesthesia, neuropathy, vertigo
Endocrine :
Constipation, dysphagia, enanthema, eructation, esophagitis, gastric ulcer, 
gastritis, gastroenteritis, gingival bleeding, glossitis, peptic ulcer, 
salivary gland enlargement, tongue disorder, tooth disorder
Abscess, bacterial infection, cellulitis, folliculitis, fungal infection, 
herpes simplex, herpes zoster, renal abscess, moniliasis, tonsillitis, viral 
Hematologic :
Anemia, epistaxis, leukopenia, lymphadenopathy
Liver and Biliary System:
Metabolic and Nutritional:
Diabetes mellitus, hyperkalemia, hyperuricemia, hypoglycemia
Musculoskeletal System:
Arthralgia, bone fracture, bursitis, joint dislocation, myalgia, stiffness, 
synovial cyst, tendon disorder
Neoplasms :
Breast fibroadenosis, carcinoma
Anxiety, confusion, decreased libido, emotional lability, impaired 
concentration, increased libido, nervousness, paroniria, somnolence etc.
Reproductive (Female) :
Breast pain, uterine hemorrhage
Respiratory System :
Abnormal chest sounds, bronchospasm
Skin and Appendages :
Abnormal pigmentation, angioedema, dermatitis, dry skin, eczema, nail 
disorder, pruritus, skin disorder, urticaria
Special Senses:
Abnormal vision, cataract, conjunctivitis, deafness, eye pain, taste 
perversion, tinnitus, vestibular disorder
Urinary System :
Abnormal urine, hematuria, increased BUN, micturition urgency, nocturia, 
polyuria, pyelonephritis, urinary incontinence
Body as a Whole:
Fever, flushes, hot flushes
Cardiovascular :
Chest pain
Central and Peripheral Nervous System :
Appetite increased, insomnia, dizziness, nervousness, vertigo
Abdominal distention, constipation, gingival bleeding
Liver and Biliary System:
Neoplasms :
Skin malignancies (squamous cell and basal cell carcinomas)
Platelet, bleeding, and clotting disorders, red blood cell disorder
Infection, viral and other infection
Skin and Appendages :
Acne, folliculitis, keratosis, pruritus, rash, dry skin
Urinary System:
Micturition frequency
Abnormal vision.
Mild hypomagnesemia and hyperkalemia may occur but are asymptomatic. 
Increases in uric acid may occur and attacks of gout have been rarely 
reported. A minor and dose related hyperbilirubinemia has been observed in 
the absence of hepatocellular damage. Cyclosporine therapy may be associated 
with a modest increase of serum triglycerides or cholesterol.
Side Effects by Body System
BK virus associated nephropathy has been associated with serious outcomes, 
including deteriorating renal function and renal graft loss.
Elevations in serum creatinine and BUN are common during cyclosporine 
therapy and do not necessarily indicate allograft rejection.
In addition, cyclosporine-induced hyperuricemia may predispose the patient 
to renal calculi.
Renal insufficiency is dose-related. It is often accompanied by 
hypertension. Cyclosporine causes a reversible reduction in renal blood flow 
and glomerular filtration rate. The mechanism of cyclosporine-induced 
nephrotoxicity is now considered to be vasoconstriction of the afferent 
arterioles. ET1 is also considered to be a key substance of 
cyclosporine-induced nephrotoxicity. Mild nephrotoxicity generally responds 
to reductions in cyclosporine doses. A chronic, progressive nephrotoxicity 
may also occur in which discontinuation of cyclosporine fails to alleviate 
the renal insufficiency. Renal biopsies from these patients may demonstrate 
interstitial fibrosis, tubular atrophy, global or segmental 
glomerulosclerosis, or smooth vascular muscle damage. It has been suggested 
that higher cumulative doses or high cyclosporine trough levels may be 
associated with the development of interstitial fibrosis.
Renal function should be closely monitored. Differentiation between 
cyclosporine-induced nephrotoxicity, allograft rejection, and other causes 
of impaired renal function should be made before considering cyclosporine 
dosage adjustments.
The use of nonsteroidal anti-inflammatory agents in combination with 
cyclosporine may increase the risk of renal toxicity, especially in 
rheumatoid arthritis patients. Intact renal prostaglandins are necessary for 
maintaining adequate renal blood flow in patients treated with cyclosporine. 
Renal deterioration may occur independent of changes in cyclosporine levels.
Renal side effects including renal insufficiency (up to 38%) and BK virus 
associated nephropathy have been reported. A chronic, progressive, 
irreversible nephrotoxicity has also been reported. Elevations in serum 
creatinine and BUN are common during cyclosporine therapy and do not 
necessarily indicate allograft rejection. A case of hemolytic uremic 
syndrome (HUS) associated with cyclosporine therapy has been reported. A 
fatal case of acute tubular necrosis has been reported. In addition, 
cyclosporine-induced hyperuricemia may predispose the patient to renal 
Nervous system:
Seizures in patients on cyclosporine therapy may be associated with 
hypomagnesemia or concomitant high-dose corticosteroids. In addition, 
hypercholesterolemia and hypertension may contribute to cyclosporine 
neurotoxicity. Hypomagnesemia and hypercholesterolemia allow easier 
diffusion of cyclosporine across the blood-brain barrier potentiating 
A review of cyclosporine-induced neurotoxicity revealed incidence after 
liver transplantation. Intravenous administration of cyclosporine was 
associated with more severe reactions such as psychosis, however severe 
reactions occurred rarely. MRI abnormalities were seldom found. Only 61% of 
patients that experienced neurotoxicity had cyclosporine trough levels 
suggestive of toxicity.
The speech disorder leading to mutism which has been associated with 
cyclosporine therapy was reversible.
The permanent blindness which was reported in patients was suspected to be 
due to neurotoxicity associated with elevated cyclosporine levels. 
Dechallenge with cyclosporine did not reverse the blindness . The blindness 
occurred over a 36 hour period 3 weeks following a kidney-pancreas 
transplant. The cyclosporine trough level was at its highest on the day of 
complete blindness (495 ng/mL). The mechanism by which cyclosporine induces 
neurologic blindness is unknown.
Nervous system side effects of cyclosporine have included tremors (to 55%) 
and headache (to 15%). Depression, somnolence, decreased visual acuity, 
confusion, paresthesias, seizures, and a reversible speech disorder leading 
to mutism have also been associated with cyclosporine therapy. Three cases 
of leukoencephalopathy have also been reported.
Dermatologic side effects of cyclosporine have included hypertrichosis acne 
and pruritus. Cyclosporine has been associated with pilosebaceous lesions, 
including hypertrichosis, epidermal cysts, keratosis pilaris, acne, 
folliculitis, sebaceous gland hyperplasia, and cutaneous malignancies. A 
case of erythroderma resembling Sezary syndrome with lymphocytic infiltrates 
of the skin has been reported. Cases of folliculodystrophy and 
pseudoporphyria have also been reported.
Hepatic side effects have been common, occurring in up to 50% of patients, 
generally mild and self-limited, and manifest as elevated bilirubin, serum 
transaminases, and alkaline phosphatase values. In addition, cholestatic 
jaundice has been reported.
A syndrome characterized by thrombocytopenia and microangiopathic anemia is 
reported in some patients.
Hematologic side effects have included leukopenia anemia, and 
Metabolic side effects of cyclosporine have included significant 
hyperkalemia, which is sometimes associated with hyperchloremic metabolic 
Gastrointestinal side effects have included gum hyperplasia , diarrhea , 
nausea and vomiting , anorexia, abdominal discomfort, and reports of upper 
gastrointestinal bleeding. Pancreatitis has also been reported.
Study has reported that reduced basal and stimulated nitrous oxide 
production in cyclosporine-treated renal transplant recipients. The authors 
stated that this suggests endothelial dysfunction, and may explain the 
increased risk of premature atherosclerosis and cardiovascular death. They 
felt this might also provide, at least in part, a potential mechanism to 
explain cyclosporine-induced hypertension.
Cardiovascular side effects have included hypertension induced by 
cyclosporine. Myocardial infarction has also been reported rarely.
Endocrine side effects of cyclosporine have included hypertriglyceridemia, 
increases in serum prolactin, decreases in serum testosterone, gynecomastia, 
hyperglycemia, and hypertrichosis.
Other side effects including a significant risk of acute rejection and death 
and/or graft loss have been reported. Cases of trichomegaly has been 
reported. A cases of calcineurin inhibitor induced pain syndrome (CIPS) has 
also been reported.
Hypersensitivity side effects to cyclosporine have occurred.
Anaphylaxis, manifest as acute dyspnea, tachypnea, pruritus, rash, and chest 
discomfort has been reported in rare cases after intravenous administration 
of cyclosporine.
A manifestation of neurotoxicity induced by cyclosporine (which has occurred 
in transplant patients more frequently than in other indications) is optic 
disc edema including papilledema, with possible visual impairment, secondary 
to benign intracranial hypertension.
Ocular side effects have included reports of pseudotumor cerebri, which 
resolved rapidly upon discontinuation of cyclosporine, and optic disk edema. 
Permanent blindness has been reported in one patient. A cases of 
cyclosporine-induced retinal toxic blindness has also been reported.
Oncologic side effects including fatal cases of metastatic angiosarcoma 
during cyclosporine and prednisone immunosuppression (after kidney 
transplantation) have been reported.
The development of neoplasms, particularly lymphomas and skin malignancies, 
is more likely in immunosuppressed patients.
In a large study, an increased incidence of lymphoma and Kaposi's sarcoma 
was found in patients treated with cyclosporine relative to those treated 
with a combination of azathioprine and prednisone. In some reported cases of 
B-cell lymphoma, the Epstein-Barr virus genome was found in the malignant 
cells, suggesting opportunistic infection during a cyclosporine-induced 
immunosuppressed state.
Immunologic side effects have included an increased patient susceptibility 
to opportunistic infections due to cyclosporine-induced immunosuppression.
Accelerated hepatitis B and C infections, sometimes resulting in hepatic 
necrosis, Pneumocystis pneumoniae infections, as well as other viral, 
fungal, and bacterial infections have been reported in patients treated with 
cyclosporine. An in vitro study demonstrated enhanced intracellular 
cytomegalovirus production and virus spread, indicating an increased risk of 
CMV infection in cyclosporine-treated patients.
Local side effects including a cases of recurrent infusion phlebitis have 
been reported.
Respiratory side effects have included respiratory arrest and aspiration 
pneumonia in one patient that lead to the death of that patient.
Apotex subjected me to the most horrifying experiences imaginable.
Apotex (my former employer) ravaged me (my system)! Apotex exposed me with 
out any personal / collective protection to well over 4000 very potent 
chemicals / actives. The human nervous system is particularly vulnerable to 
toxic-chemical insults. Many chemicals can permanently disrupt nervous 
system function.
Many of those side effects I do suffer includeing abnormal pigmentation, 
skin disorder , skin malignancies (basal cell carcinomas), very painful a 
soft-tissue mass (soft-tissue tumors/soft-tissue lumps etc.
DECIVED, ABONDONED BY Ontario Labour Board, Ontario Ombudsmen Office, FAIR 
PRACTICES COMMISION, Ontario Worker Adviser, Ontario Human Rights 
Commission, Ontario Human Rights Tribunal, WSiB, -GOVERNMENT of ONTARIO. 
Unfortunately in my case many key Government Agencies turn out to be 
dysfunctional and criminal.
The issue/problem becomes politically sensitive and concluding it in lawful 
manner is in the best interest of General Public.
Apotex's victim